The QUEST Global initiative: QUality of life Evaluation STudy: Assessing Health Related Quality of Life in patients receiving medicinal cannabis.

ittle Green Pharma Ltd0 个研究点目标入组 12,000 人开始时间: 2023年5月29日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•All of the following must be satisfied for enrollment in the study:
•adult patients (aged 18 years)
•patient has been identified as eligible to receive medicinal cannabis by a TGA approved Authorised Prescriber or via the Special Access Scheme (SAS-B) and the doctor has sought and obtained TGA approval for Little Green Pharma (LGP) products for their patient.
•patient is able to read and understand English
•patient is able to provide informed consent
•patient has not started any prescribed medicinal cannabis therapy in the previous 4 weeks; or started prescribed LGP medicinal cannabis therapy within the previous 2 days (we expect no therapeutic benefit within 2 days) and has not received any prescribed medicinal cannabis therapy in the previous 4 weeks
•patient has a life expectancy of more than 3 months .

•Patients will be excluded from the study if any of the following criteria apply:
•are unconscious or confused
•have cognitive impairment
•are pregnant or breastfeeding
•are unable to speak, read and/or write in English
•are denied access to medicinal cannabis under the relevant Special Access Scheme (SAS) for their country of registration
•are unable to provide informed consent
•are already receiving prescribed medicinal cannabis treatment for more than 2 days
•have received prescription medicinal cannabis within the last 4 weeks (excluding previous 2 days)

发起方

ittle Green Pharma Ltd